Founded by CSL Behring’s namesake, Emil von Behring, who won the first Nobel Prize for medicine in 1901, today‘s pharmaceutical and biotech companies at the “Behringwerke“ industrial hub still represent the leading edge of scientific discovery.
In Marburg, CSL Behring benefits from intensive networking between the health and medical sectors and the partnerships with excellent universities and research institutes, says Lars Groenke, M.D., Vice President, R&D Respiratory and Managing Director of the CSLBehring Innovation GmbH. In 2022, CSL Behring will increase its footprint with the opening of a new, seven-story R&D facility, including state-of-the-art lab space, for 500 CSL Behring research staff.
“For us at CSL Behring, Marburg is the location of choice,” says Groenke. “Today, as a global biotechnology leader and part of the international CSL Group, we specialize in producing and researching plasma-based and recombinant therapies – driven by our promise to save and improve lives.”
And yet: for all the international importance of the location, Marburg is still the pastoral university town that boasts a medieval castle. Pretty much like, “Marburg-Biedenkopf: actually, like Berlin or Munich – only with more sheep.”
